Adverse Effects of Sympathetic Activation Should Not Be Neglected During the COVID-19 Pandemic
Most people associate COVID-19 with respiratory symptoms like coughs and shortness of breath—but the virus’s impact on the heart and blood vessels is a growing concern, especially for those with pre-existing conditions. A 2021 study from researchers at Hebei Medical University (Shijiazhuang, China) highlights a hidden driver of many COVID-19-related cardiovascular complications: overactivation of the sympathetic nervous system—the body’s “fight-or-flight” response that normally helps us handle stress, but can harm us when it stays turned on too long.
What We Know About SARS-CoV-2 and the Body
COVID-19 is caused by the SARS-CoV-2 virus, which uses a protein called angiotensin-converting enzyme 2 (ACE2) to enter cells. ACE2 is found in high levels in the lungs (explaining why respiratory issues are common) but also in the heart, blood vessels, and other organs. While most people get mild flu-like symptoms, severe cases can progress to pneumonia, acute respiratory distress syndrome (ARDS), or shock.
But here’s the key: People with pre-existing cardiovascular conditions—like high blood pressure, diabetes, or heart disease—are twice as likely to develop severe COVID-19 and die from it. Even people without prior heart problems can experience cardiac injury, irregular heartbeats, or blood pressure changes—and these complications worsen outcomes.
Why Direct Viral Damage Isn’t the Whole Story
Scientists initially thought COVID-19 harmed the heart either by directly infecting it or triggering a “cytokine storm” (a dangerous overreaction of the immune system). But pathological studies (like one published in Lancet Respiratory Medicine) found little evidence of viral damage or severe inflammation in the heart tissue of COVID-19 patients.
Take the case of a 64-year-old woman with COVID-19: She developed life-threatening heart failure (low ejection fraction, cardiogenic shock) and rapid heartbeats—but tests showed no myocarditis (heart muscle inflammation) or cytokine storm. The researchers concluded her symptoms were driven by sympathetic overactivation—her body’s stress response was stuck in “on” mode, overwhelming her heart.
Sympathetic Overactivation: A Hidden Threat
The sympathetic nervous system normally kicks in during emergencies, releasing hormones like adrenaline to increase heart rate and blood pressure. But when it stays overactive for weeks (or longer), it damages the heart:
- It speeds up disease progression in chronic conditions like heart failure, arrhythmias (irregular heartbeats), and high blood pressure—all common COVID-19 complications.
- It triggers Takotsubo syndrome (sometimes called “broken heart syndrome”), a temporary heart dysfunction often misdiagnosed. COVID-19 patients with acute myocarditis have shown a “reverse” form of this syndrome, linked to sympathetic activation.
- It explains long-lasting tachycardia (rapid heart rate) seen in both COVID-19 and SARS patients—one study found SARS-related tachycardia persisted for weeks, likely from unregulated fight-or-flight responses.
Even more telling: A New England Journal of Medicine study found people taking beta-blockers (drugs that calm the sympathetic system) were slightly less likely to test positive for COVID-19. While this doesn’t prove causation, it suggests dampening the fight-or-flight response could offer protection.
How Does COVID-19 Overactivate the Sympathetic System?
The researchers outline four key ways SARS-CoV-2 ramps up the sympathetic response:
- Hypoxia: Breathing problems (like ARDS) reduce oxygen in the blood. The body’s “oxygen sensors” (carotid bodies) send signals to the brainstem, which overactivates the sympathetic system to compensate.
- Neuroinflammation: SARS-CoV-2 may invade the brain and inflame areas that control the sympathetic system (like the nucleus of the solitary tract or hypothalamic paraventricular nucleus).
- Cytokine invasion: Inflammatory proteins from the immune response can cross the blood-brain barrier and damage brain regions that regulate stress.
- Anxiety: Fear of COVID-19 or hospitalization releases extra adrenaline, worsening sympathetic overactivation.
Could Sympathetic Inhibitors Help?
While there’s no cure for COVID-19 yet, the study suggests drugs that calm the sympathetic system—like beta-blockers, central sympatholytics (e.g., clonidine), or imidazoline receptor agonists—might improve outcomes. This is especially relevant for people with pre-existing conditions, where sympathetic overactivation is already a problem.
The Bottom Line
COVID-19 is more than a respiratory disease—it’s a systemic illness that disrupts the body’s stress response in dangerous ways. The Hebei Medical University study reminds us that sympathetic overactivation is a critical factor in cardiovascular complications, even for people without prior heart issues. As we continue to learn about COVID-19, paying attention to this “hidden” driver could save lives—especially for those at highest risk.
This study was conducted by Sheng Jin, Jing Dai, Xu Teng, and Yu-Ming Wu from the Department of Physiology and Clinical Diagnostics at Hebei Medical University, with support from the National Natural Science Foundation of China and other regional grants.
Original research published in Chinese Medical Journal (2021;134:413–414).
For full study details, visit doi.org/10.1097/CM9.0000000000001106
References (key studies cited):
- Circulation (2020): COVID-19 and cardiovascular disease risk.
- Lancet Respiratory Medicine (2020): Pathological findings of COVID-19-related heart damage.
- Circulation (2020): Case study of COVID-19-induced cardiac decompensation.
- New England Journal of Medicine (2020): Beta-blockers and COVID-19 risk.
- European Heart Journal (2020): Takotsubo syndrome in COVID-19 patients.
- Postgraduate Medical Journal (2006): SARS-related tachycardia and sympathetic activation.
Was this helpful?
0 / 0